S&R Associates represented Morgan Stanley in connection with the delivery of a fairness opinion to the board of directors of Biocon Limited, a listed biopharmaceutical company, in relation to a proposed acquisition of the remaining shareholding in its subsidiary, Biocon Biologics Limited, held by Mylan Inc. (Viatris), Serum Institute Life Sciences, Tata Capital Growth Fund II and Activ Pine LLP for consideration including cash and Biocon Limited shares.
The S&R team was led by partner Jabarati Chandra and counsel Sushmita Sur.
For reference, please see the stock exchange announcements below in relation to the transaction:
https://www.bseindia.com/xml-data/corpfiling/AttachHis/6994093c-1262-46a6-8b1f-beb2a2561444.pdf
https://www.bseindia.com/xml-data/corpfiling/AttachHis/30262fd1-004b-4485-b60f-35b9dacd2105.pdf